Pradimicin BMY-28864 (PRM) has also been reported as a chemically modified derivative for improved solubility and antifungal activity. Yamamoto et al. found that PRMinhibited the fusion of human immunodeficiency virus to T cells by binding to high-mannose glycans on gpl20. Glycosidase Inhibitor Treatment Cells (1 x 105/ml) were cultured with DMJ (50-1000 jug/ml), CAS (20-500/ig/ml) or SW (10~100/ig/ml) under the same conditions described above. After incubation for up to 72 hours, cells were washedwith PBS (-) and used for further experiments.
Pradimicin Treatment
Cells (1 x 105/ml) were cultured with various concentrations of BMY-28864 (0-lOO^g/ml) under the sameconditions described above. After incubation for up to 72 hours, cells were washed with RPMI 1640 and the cell viability was determined by MTSmethod.
Binding of FITC-Con A and FITC-PRM After the glycosidase inhibitor treatment, U937 cells ,(5 x 105) were incubated with FITC-Con A (50/zg/ml) for 24 hours in PBS (+) (1 ml) or FITC-PRM (50fig/ml) for a given length of time in RPMI 1640 (2ml) at 37°C in dark. After washing with PBS (+) three times, the cells were suspended in PBS (+) (3ml) and the fluorescence emission at 522nmwas measured with an excitation wavelength of 494 nm.
Cell Viability Assay Cell viability was determined by MTSmethod according to the supplier's protocol (Promega Corp.).
Cells were plated in a 96-well plate (2 x 105 cells/well) and cultured with MTS/PMS (20: 1, 20/d) for up to 4 hours. Reaction was stopped by the addition of 10% SDS (25^1) and the optical density was determined using an ELISA reader at 490 nm. The percent viability wascalculated.
Results

Preparation of DMJ-treated U937 Cells
It has been reported that coincubation of mammalian cells with 1-deoxymannojirimycin (DMJ), a specific inhibitor of mannosidase I, induces the accumulation of (Man)9(GlcNAc)2, resulting in the expression of high-mannose type oligosaccharides at the cell surface.10'11* The growth of U937 cells was initially examined in the presence of various concentrations of DMJ. Coincubation with 100~500//g/ml DMJ did not affect the doubling time (18hours).
At 1000jug/ml of DMJthe growth was slightly inhibited and the doubling time was prolonged from 18 to 20hours. Morphological change was not observed even at 1000 //g/ml DMJ. Above results confirmed that U937 cells were not affected by less than 500/ig/ml DMJregarding to the growth rate and the morphology. 18 hours.
Effect of PRMon DMJ-treated Cells PRM-induced cell death was investigated timedependently in parallel with the measurement of binding of pradimicin. Pradimicin BMY-28864 (PRM) and FITC-labeled pradimicin FA2 (FITC-PRM) were used for the cytotoxic assay and the binding study respectively. After 48 hours of incubation with DMJ,cells were treated with 50/jg/ml PRM in the absence of DMJ (Fig. 2A) .
The percentage of the living cells decreased by 53%after cell growth and the decrease of the binding amount of FITC-PRMcould be explained by the regeneration of normal (complex type) oligosaccharides at the cell surface in the absence ofDMJ. To prove this hypothesis we incubated the cells with PRMin the continuous presence of DMJ (Fig. 2B) . The viability was 26% after 72hours and the binding took place rapidly until 6hours and continued slowly up to 72hours.
Effect of Glycosidase Inhibitors on PRM-induced Apoptosis
Castanospermine (CAS) and swainsonine (SW) inhibit glycosidases responsible for TV-linked oligosaccharide processing. We studied the effect of PRMon the cells which had been treated with CAS and SW in addition to DMJ. The alteration in types of the cell surface oligosaccharides in U937 cells were analyzed by comparing the binding of FITC-Con A and FITC-PRM (Fig. 3) . The optimal concentration for CAS and SW was determined by measuring the cell growth in the range of 20~500jUg/ml and 10~100jUg/ml respectively with referring to the reported values. FITC-Con A bound to CAS-treated cells 80% over control whereas the binding amount of FITC-PRMwas not increased. DMJ-treated cells. The above result obviously indicates that PRMrecognizes and binds to the oligosaccharides of which expression was induced by DMJ treatment. The effect of PRMon the glycosidase inhibitor-treated cells was examined next. After the incubation with an appropriate concentration of each glycosidase inhibitor for 48hours, cells were treated with 50pig/ml PRMfor 24hours (Fig. 4) . The viability of DMJ-treated cells was 42% of control, whereas CAS-and SW-treated cells were completely insusceptible to PRM.
Discussion
We have shown that PRM induced apoptosis of DMJ-treated U937 cells dose-dependently and the cytotoxic effect of PRMwas enhanced depending on the DMJ concentration at the preincubation.7) The similar effect of PRMwas observed in HL-60 and PC12 cells, suggesting the presence ofa general mode of action. Since the role ofDMJin this system was to inhibit mannosidase I, it seemed obvious that the cell surface glycan was critical for apoptosis induction. Additionally, the involvement of mannose-containing oligosaccharides was strongly suggested by the property of PRMwhich recognizes D-mannosidesin the presence of Ca2+, and PRMwas thought to bind to terminal mannose residues at the cell surface since the binding was dependent on the DMJtreatment. In fact, Fig. 2 clearly shows that the apoptosis was induced in response to the PRMbinding. Under a fluorescence microscope, FITC-PRMbound to the cell surface uniformly and any localization was not observed (data not shown). Furthermore, we studied the effect of PRMon other types of oligosaccharide containing terminal mannoses (Fig. 5 ). In the biosynthesis of TV-linked oligosacchar ide, (Glc)3(Man)9(GlcNAc)2 is first transferred from dolichol pyrophosphate to asparagine residues of proteins, and three glucoses are removed by glucosidases I and II to afford a high-mannose type oligosaccharide, (Man)9(GlcNAc)2. Castanospermme (CAS) inhibits both glucosidases I and II and it is reported that CAS promotes the formation of (Glc)3(Man)9(GlcNAc)2 more than 70%over control in virus12) and mammalian cells.13) The high-mannose type glycan is transformed into complex type one through the processing by mannosidases I and II. In the presence of swainsonine (SW), a potent inhibitor of mannosidase II, the conversion of high-mannose type to complex type is blocked and the formation of hybrid type such as (NeuAc)(Gal) (GlcNAc)(Man)5(GlcNAc)2 is preferred.14~16) CASand SW-treated U937 cells were not sensitive to PRM and the level of FITC-PRM binding to those cells was sameas that to the control. This result indicates the recognition ofa mannose-containing glycan by PRMwas specific. The glycosidase inhibitors employed in this study are effective on the processing of TV-linked oligosaccharides, but not on the proteins. Though it is still under investigation whether PRMfunctions extracellularly or intracellularly, it is supposed that PRM binds to a high-mannose type oligosaccharide on a cell surface protein, and the protein transmits the apoptotic signal to the cell. In summary, we demonstrated evidences suggesting that PRMinduces apoptosis in U937 cells through the interaction with high-mannose type oligosaccharide, presumably (Man)9(GlcNAc)2, at the cell surface.
influenza virus-induced cell fusion by pradimicin, a low molecular weight mannose-binding antibiotic. 
